Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note

Bristol Myers Squibb (BMY) closed the most recent trading day at $60.65, moving +1.54% from the previous trading session. This move lagged the S&P 500's daily gain of 2.91%. On the other hand, the Dow registered a gain of 2.49%, and the technology-centric Nasdaq increased by 3.83%. Prior to today's trading, shares of the biopharmaceutical company had lost 4.19% was narrower than the Medical sector's loss of 9.63% and the S&P 500's loss of 7.64%.Investors will be eagerly watching for the performance of Bristol Myers Squibb in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on April 30, 2026. The company is forecasted to report an EPS of $1.46, showcasing a 18.89% downward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $10.86 billion, reflecting a 3.02% fall from the equivalent quarter last year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.26 per share and revenue of $47.03 billion. These totals would mark changes of +1.79% and -2.42%, respectively, from last year. It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.14% higher. Right now, Bristol Myers Squibb possesses a Zacks Rank of #3 (Hold). Digging into valuation, Bristol Myers Squibb currently has a Forward P/E ratio of 9.54. For comparison, its industry has an average Forward P/E of 17.84, which means Bristol Myers Squibb is trading at a discount to the group. We can also see that BMY currently has a PEG ratio of 0.17. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.49 based on yesterday's closing prices. The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 148, this industry ranks in the bottom 40% of all industries, numbering over 250. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks